Purpose We review recent advances in the biologic understanding and treatment of
childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), identify …

Treating adolescents and young adults (AYAs) diagnosed with cancer is a challenge. Acute
myeloid leukemia (AML) which is usually diagnosed in a previously healthy kid, requiring …

The prognosis of pediatric acute myeloid leukemia (AML) has improved significantly over the
past decades. However, few papers have actually illustrated this improvement, and many …

Despite major improvements in outcome over the past decades, acute myeloid leukemia
(AML) remains a life-threatening malignancy in children, with current survival rates of∼ …

Purpose Karyotype is an independent indicator of prognosis in acute myeloid leukemia
(AML) that is widely applied to risk-adapted therapy. Because AML is rare in children, the …

Acute myelogenous leukemia (AML) accounts for about 20% of the acute leukemias seen in
children. In contrast to childhood acute lymphoblastic leukemia (ALL), only modest …

There have been significant improvements in the outlook for children with acute leukaemia
but these advances are only available to a minority of the world's children. There is still room …

Acute myeloid leukemia (AML), a heterogeneous group of diseases with variable responses
to the same therapy, comprises nearly a quarter of childhood acute leukemias. Although …

During the past decade, the outcomes of pediatric patients with acute myeloid leukemia
(AML) have plateaued with 5‐year event‐free survival (EFS) and overall survival (OS) of …

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …